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ABSTRACT 
Objective 
Medication arrangements for patients with severe mental illness (SMI), including 
schizophrenia and bipolar disorder, can be complex. Some have shared care between 
primary and secondary services whilst others have little specialist input. This study 
investigated the contribution a specialist mental health clinical pharmacy team could make 
to medicines optimisation for patients on the SMI register in primary care. Research shows 
that specialist mental health pharmacists improve care in inpatient settings. However little 
is known about their potential impact in primary care. 
 
Method 
Five General Practice (GP) Surgeries were allocated half a day per week of a specialist 
pharmacist and technician for 12 months. The technician reviewed primary and secondary 
care records for discrepancies. Records were audited for high dose or multiple 
antipsychotics, physical health monitoring and adherence. Issues were referred to the 
pharmacist for review. Surgery staff were encouraged to refer psychotropic medication 
queries to the team. Interventions were recorded and graded.    
 
Results 
316/472 patients on the SMI register were prescribed antipsychotics or mood stabilisers. 23 
(7%) records were updated with missing clozapine and depot information. Interventions by 
the pharmacist included clarifying discharge information (12/104), reviewing high dose and 
multiple antipsychotic prescribing (18/104), correcting errors (10/104), and investigating 
adherence issues (16/104), following up missing health checks (22/104) and answering 
queries from surgery staff (23/104). Five out of six interventions possibly preventing hospital 
admission were for referral of non-adherent patients.    
 
Conclusion 
The pharmacy team found a variety of issues including incomplete medicines reconciliation, 
adherence issues, poor communication, drug errors and the need for specialist advice. The 
expertise of the team enabled timely resolution of issues and bridges were built between 
primary and secondary care.  
 
 
Key words 
Clinical pharmacy, antipsychotics, primary care, mental health, medicines optimisation. 
 
 
INTRODUCTION 
Specialist Mental Health Pharmacists have been working successfully in secondary care to 
improve medicines optimisation for patients with severe mental illness (SMI) including 
bipolar disorder and schizophrenia.[1] Interventions include providing drug information to 
staff and patients, promoting drug adherence and ensuring safe and effective medicines 
use. [2] Issues of particular concern include antipsychotic polypharmacy and high dose 
antipsychotic prescribing, which are poorly evidenced and can increase side effects such as 
arrhythmias and movement disorders. [3] Patients with schizophrenia and bipolar disorder 
are also more likely to die early due to health problems, [4] which may in part be due to 
metabolic effects of medication. Annual physical health monitoring is recommended but can 
be missed. It has also been estimated that up to half of people with schizophrenia and 
bipolar disorder do not take their medication as prescribed, which may increase relapse and 
suicide rate. [5] 
In the last 20 years there has been a significant reduction in mental health beds. [6] Some 
patients may be cared for in the community by Community mental Health Teams (CMHTs) 
which form part of secondary care. However increasing numbers of people are being cared 
for by solely by their GP in primary care. Initially there is a shared care approach with 
psychotropic medication being initiated and monitored by secondary care. The GP then 
takes over prescribing and monitoring once a patient is stable. In England people with an 
SMI are included on an SMI register in each GP practice and practices are monitored to 
ensure appropriate care delivery. GPs have raised concerns reporting a need for increased 
knowledge and competence regarding treatment and diagnosis of mental health conditions 
and improved co-operation between primary and secondary care. [7] Pharmacists working 
in primary care may also lack the confidence and skills needed to address medication issues. 
[8] Patients are also concerned with 22% reporting they needed more specialist input. [9] 
This study aimed to explore the gaps in service provision relating to medicines and 
determine whether a specialist pharmacy team could provide useful input for patients on 
the SMI register. In primary care, specialist input is uncommon although some benefit has 
been demonstrated for depression and dementia, [10][11] however involvement of 
specialist mental health pharmacists for SMI in a GP setting has not been explored. 
 
METHOD 
The project covered 5 surgeries across Leeds, a city in the UK, over a 12 month period from 
March 2016 to February 2017. None of the surgeries directly employed a clinical pharmacist.  
A pharmacist and pharmacy technician were each allocated half a day per week per surgery. 
The pharmacy technician undertook a preliminary audit of patients on the SMI register. 
Patients prescribed antipsychotic or mood stabilising drugs were identified. Information was 
collected on completed physical health checks and high dose and multiple antipsychotic 
prescribing. Medicines reconciliation was also carried out by comparing primary and 
secondary care patient records, with particular attention paid to patients on clozapine and 
depot antipsychotics. Missing information was updated in both primary and secondary care 
systems. The GP prescription record was scrutinised to check that prescriptions were being 
ordered by patients. A list of patients receiving depots from the practice nurse was obtained 
and patients who did not regularly attend were identified. Instances of non-adherence, 
missing physical health checks and other areas of concern were highlighted and referred to 
the pharmacist for further investigation and intervention.  
The pharmacist reviewed the medication of all patients referred by the technician using 
both GP and secondary care records. Information was recorded and analysed using excel. 
The pharmacist introduced the project to the surgeries and made themselves available for 
support with mental health medication queries. Queries were sent using a task system on 
practice information systems, with tasks being checked weekly when surgeries were visited. 
Where concerns were raised the pharmacist liaised with consultants, care co-ordinators, 
GP’s, practice nurses and community pharmacists to resolve them. Interventions carried out 
by the pharmacist were assessed and graded using a validated scale adapted from Nathan et 
al. [12] Gradings were independently assessed by a second pharmacist. An intervention was 
defined as any action taken with the aim of modifying the process of use of drugs. An 
education and training session was also organised on depot medication and shared care 
guidance as this was identified as being of particular concern by surgery staff. Training 
sessions were also organised for staff in secondary care to raise awareness of issues faced in 
primary care. 
RESULTS 
The pharmacy technicians reviewed the records of 472 patients on the SMI register. 316 
(67%) of these were currently prescribed antipsychotics or mood stabilisers. The technicians 
referred 197 cases to the pharmacists for review. Interventions were needed in 66 cases. 
Pharmacy Team Interventions 
Pharmacy technicians identified 23 patients on clozapine, an antipsychotic which is always 
prescribed by secondary care. In 5 cases (22%) this was not documented on GP systems and 
systems were updated. 66 patients were prescribed depot antipsychotics which were 
prescribed and administered by secondary care in 37 (56%) patients. In 18 (27%) cases 
depots were not recorded on GP systems and systems were updated with missing 
information. Missing letters and allergy status were also added to GP systems and 
secondary care systems. Staff at GP surgeries also raised queries with the pharmacist 
resulting in a further 38 interventions. Some of these related to more than one patient. A 
breakdown of the causes for pharmacist intervention is shown in Table 1.  
 
 
Table 1: Causes of Pharmacist Intervention 
Cause  of Intervention Number of Interventions (percentage) 
High Dose Antipsychotic 11 (10.6%) 
Antipsychotic Polypharmacy 7 (6.7%) 
Adherence Issues 16  (15.4%) 
Blood test overdue 16 (15.4%) 
Blood test out of range 6 (5.8%) 
Drug Error 10 (9.6%) 
Discharge Issues 12 (11.5%) 
Advice requested 23 (22.1%) 
Other 3 (2.9%) 
Total 104 
 
High Dose and Combination Antipsychotics prescribing 
All instances of high dose (n=11) and multiple (n= 20) antipsychotic prescribing were 
referred to the pharmacist for review who ensured that all identified patients received input 
from secondary care. Standards of additional monitoring and review suggested by the Royal 
College of Psychiatrists [13] would be difficult to maintain in primary care.  As a result 5 
(45%) patients on high doses were referred to specialist services. Seven cases (35%) of 
combination prescribing were discussed with GP’s or referred to secondary care for review 
where rationale was unclear or prescribing had occurred some time ago. One case involved 
a patient on three antipsychotics which were successfully reduced at the surgery. No further 
intervention was deemed necessary for 13 (65%) patients on multiple antipsychotics. These 
patients were under shared care between the CMHT and GP. Combinations involved 
clozapine plus aripiprazole or amisulpride, believed helpful in treatment resistant 
schizophrenia. [14]  
 
Adherence Issues 
All 16 instances where prescriptions had not been ordered were investigated. In 8 (50%) 
cases CMHTs were contacted and informed. In many cases they were unaware their patient 
was non-adherent. In two cases, where there was no current CMHT involvement, urgent 
appointments were given by CMHT to review the patient and medication was restarted. In 
6(38%) cases the patients had stopped for sound reasons or were abroad for extended 
periods and GP records were updated accordingly.  
Physical Health Monitoring Issues 
In 22 cases physical health monitoring involving blood tests or electrocardiographs (ECG) 
were referred to the pharmacist. Results were overdue in 16 (73%) cases and out of range in 
6 (27%) cases. Reasons for overdue tests included patient not attending despite requests 
from surgery, lack of clarity whether tests should be done by primary or secondary care and 
patient being abroad for an extended period. Clarity was sought where possible and non-
adherent patients were seen in clinic, contacted over the phone or referred to secondary 
care for follow up if deemed necessary. Where results were out of range, repeat tests were 
requested and prescribers notified. Some patients were being monitored twice – at CMHT 
clinics and the GP surgery, with neither team aware of this duplication. 
Drug Errors 
Ten cases of drug error were discovered. All were referred to the pharmacist and corrected. 
Errors included wrong doses and unclear directions. Prescribers were contacted and 
informed as feedback has been shown to help reduce errors. [15] In 50% of cases errors 
were due to poor communication from secondary care the remaining 50% were due to 
instructions from secondary care being missed by surgeries.  
Discharge Issues 
Eleven cases of incomplete or unclear discharge information highlighted communication 
issues between primary and secondary care. This is likely to be an underestimate of the 
problem as not all surgeries routinely communicated this. Investigation showed poor 
understanding of shared care guidelines, with GP’s being asked to titrate or start 
antipsychotic medication when the guidelines state this should be done by secondary care. 
In other cases information was missing, for example no reasons given for starting and 
stopping medication in hospital and no details of physical health checks carried out.  GP’s 
were often left uncertain whether they were responsible for physical health monitoring or 
depot administration and who to contact if patients were non-adherent, experienced 
relapse or wished to change or stop their medication. The pharmacist fed each case back to 
the staff responsible and education on discharge information was provided to secondary 
care healthcare professionals. 
Advice 
Advice was sought on a diverse range of psychiatric medication issues, mainly by GP’s. 
Examples include options for patients responding poorly to medication, antipsychotic 
reducing regimes, side effect management and depot intervals. 
Grading of interventions 
Interventions were graded in an attempt to ascertain their impact, using an adapted scale. 
[12] (Table 2) Five of the six interventions of greatest significance were for referral of non-
adherent patients. One was due to a drug error on the GP system. Grade 2 interventions 
included advice given where it would impact patient care, referrals for high dose monitoring 
and overdue physical health checks. Grade 3 interventions included cases where advice 
helped to clarify prescribing.  
 Table 2. Graded Interventions 
Grade Meaning Number of interventions (%) 
1 Very significant hospital admission prevented 6 (5.8%) 
2 Significant improved outcome if changed 42(40.4%) 
3 Somewhat significant understanding increased 32 (30.8%) 
4 No clinical significance 24 (23.1%) 
 
DISCUSSION 
This study aimed to investigate whether a specialist mental health pharmacy team could 
make improvements in medicines optimisation. The issues raised such as non-adherence, 
polypharmacy and communication problems between primary and secondary care have all 
been cited as areas where pharmacists have an important role to play in primary care. [16]  
Medicines reconciliation by registered pharmacy technicians has been shown to be an 
effective way to rectify discrepancies in inpatient mental health services. [17] In this study 
technicians identified discrepancies in both the primary and secondary care medication 
records and updated information, for example information on clozapine and depots. 
Omissions such as this are reported to be the most common form of discrepancy because 
they are prescribed by specialist services. [18][19] Clozapine can cause serious 
complications such as agranulocytosis, myocarditis and severe constipation. Smoking 
cessation can increase levels leading to severe toxicity[20] If the GP is unaware of the full 
medication picture, reasons for physical ill health may be missed.  
The preliminary audit was also carried out by technicians who identified and solved  
problems, for example contacting patients who needed to attend for depots. The 
pharmacist was able to concentrate on more clinically focused issues that were either 
referred from the surgeries or from the technician, enabling a more streamlined process.  
Only 316 (67%) of patients on the SMI register were on antipsychotics or mood stabilisers, 
an unexpected finding. This was explored in one surgery and reasons included inaccurate 
coding or past symptoms that no longer required treatment with these medications.  
Many surgery staff we spoke to felt that communication between primary and specialist 
mental health services needed improvement. Incomplete discharge information from 
secondary care caused concern and wasted staff time. Such issues have been widely 
reported [18] [19] and  can result in readmission, severe harm and fatalities. [21] A number 
of measures were in place that are believed to improve the communication of information 
including a computerised shared care record and a standardised psychiatric discharge 
summary, [19][3] but problems with these measures were found. The preliminary discharge 
letter from hospital was often not followed up with more detailed communication. The 
standardised template was also only used by medical staff despite the fact that care co-
ordinators (commonly nurses or occupational therapists) also discharged patients to GP’s. 
The shared care record was not fully integrated with GP systems so medication prescribed 
by secondary care services did not automatically appear on GP lists. Many of these issues 
could be improved with an integrated information system. [22]  
Staff also welcomed having specialists available in the surgeries to offer advice on mental 
health medication. Secondary care offers a pharmacist medicines information service but 
this is rarely accessed suggesting a visible presence in the surgeries increased accessibility of 
this service. Education sessions were held by the pharmacy team involved in the project for 
both primary and secondary care staff to highlight some of the issues uncovered and 
increase understanding between services. 
A relatively low number of patients (22 (7%)) had outstanding health checks relating to their 
medication. Shared care guidance and automatic recall systems at the surgeries might 
account for this. [23] Gaps were typically due to patients not attending the surgery despite 
texts and letters. Numerous reasons have been put forward as to why some people do not 
engage including lack of information and limited awareness of cardiovascular risk . [24] All 
non-attenders were referred to CMHT as additional specialist input may help to encourage 
these patients. [23] Many patients had only one or two outstanding tests, suggesting a lack 
of consistency in monitoring, for example blood tests and weight checks were carried out by 
different people who lacked specialist knowledge. Educational sessions were provided by 
the pharmacist in an attempt to address this. Tests carried out by secondary care were not 
always communicated with GP’s leading to gaps in the records and duplicate testing. Again 
an integrated IT system would be beneficial. 
Non-adherence led to 5 out of a total of 6 interventions considered to be of high 
significance. Patients not attending for depot medication caused a great deal of concern for 
some practice nurses who had limited time to follow up patients. Studies have shown that 
practice nurses may lack confidence and training in this area. [25] The extent of non-
adherence is likely to be an underestimate as GP’s systems highlighted only those 
prescriptions not ordered by patients. They do not show whether medication is actually 
collected from pharmacies or taken by patients.  Adherence is complex and there are many 
reasons why patients do not take medication as prescribed including side effects, forgetting 
and lack of efficacy. [26] Our study showed that care co-ordinators (who may have little 
medication training) were often unaware that their patients were not ordering medication 
which suggests that this aspect may be neglected during consultations.  
High doses of antipsychotics were prescribed in 11 (3.5%) of patients and 20 (6%) were on 
combination antipsychotics. These figures are similar to those from other studies in primary 
care.  [27] We referred  patients to secondary care as standards for regular monitoring and 
review suggested by the Royal College of Psychiatrists [13] would be difficult to maintain in 
primary care.   
Pharmacists are recognised as an underutilised resource and are currently being trained to 
take on extended clinical roles in GP surgeries to meet increasing demands on GP services. 
[28]This study suggests that specialist input may also have value in an area such as mental 
health where confidence of both GP’s and general pharmacists may be low.    
Limitations  
This is a small exploratory study incorporating aspects of audit and service evaluation, as 
such firm conclusions about the utility and cost effectiveness of a specialist service cannot 
be firmly drawn. We were also unable to follow up referred patients to see whether there 
was any dosage reduction or rationalisation of prescribing.  However the project highlighted 
gaps in service provision which could be addressed by a specialist psychiatric pharmacy 
team. Grading of interventions is by its nature subjective and relies on “guessing” outcomes 
if there had been no intervention. Using two pharmacists to independently evaluate the 
grading mitigates this only in part but the authors felt there was some value in showing how 
many interventions potentially prevented hospital admission. 
Face to face clinics were outside the scope of the project which will have limited the impact 
of the interventions in some instances. Further research is needed into the impact a 
specialist non-medical prescriber (NMP) could have and the second phase of the pilot hopes 
to incorporate this aspect. Cases of high dose and multiple prescribing could potentially be 
monitored on an ongoing basis by a specialist NMP in primary care. NMP’s could also 
benefit patients with complex needs who do not reach the threshold for acceptance into 
CMHT, for example patients who are mentally well who wish to reduce and stop 
medication.  
Audits were time consuming and finding mental health information on GP systems was 
difficult. Information about rationale for drug choices and mental health care plans do not 
have an obvious location in GP systems.  Some template development and building of 
searches is ongoing and this could help automate audits in the future and provide easier 
access to information. Clearer referral criteria for technicians to pharmacists could reduce 
the time spent reviewing records where no intervention was needed and this will be 
addressed in the next phase of the project 
 
CONCLUSION  
A variety of medicines management issues were discovered including incomplete medicines 
reconciliation, physical health monitoring, adherence, poor communication, drug errors  
and the need for specialist advice. Some of these problems are potentially serious if left 
unresolved. An integrated IT system would help resolve many of the issues but this is 
unlikely to occur soon. The strength of the specialist mental health team was that many 
issues could be resolved quickly due to expertise, experience and working knowledge of 
services and contacts in secondary care. The awareness of the issues faced by staff in 
primary care was also raised and shared. Specialist mental health teams can help to reduce 
risks, resolve issues and build bridges between primary and secondary care, improving the 
care provided to the mental health patients in primary care settings.  
Key Messages 
What is already known on the subject 
Patients with severe mental illness are increasingly cared for in primary care and access to 
specialist services can be difficult. 
Patients with severe mental illness can have complex medication needs. 
Specialist mental health pharmacists improve care in secondary care and specialist 
community services. 
What this study adds 
A specialist mental health clinical pharmacy team can identify multiple medicines issues and 
improve medicines optimisation in patients with severe mental illness in primary care. 
A specialist mental health pharmacy team can help build bridges between primary and 
secondary care. 
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